NTLA – Intellia Therapeutics, Inc.
Float Short %
36.85
Margin Of Safety %
Put/Call OI Ratio
0.36
EPS Next Q Diff
-0.07
EPS Last/This Y
1.28
EPS This/Next Y
0.38
Price
10.13
Target Price
22.12
Analyst Recom
2.22
Performance Q
-50.44
Relative Volume
0.73
Beta
2.1
Ticker: NTLA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-09 | NTLA | 9.31 | 0.37 | 0.44 | 122347 |
| 2025-12-10 | NTLA | 9.39 | 0.37 | 0.18 | 123233 |
| 2025-12-11 | NTLA | 9.55 | 0.37 | 0.42 | 123955 |
| 2025-12-12 | NTLA | 9.02 | 0.36 | 0.12 | 126309 |
| 2025-12-15 | NTLA | 9.15 | 0.36 | 0.44 | 126139 |
| 2025-12-16 | NTLA | 9.11 | 0.36 | 0.45 | 127407 |
| 2025-12-17 | NTLA | 8.86 | 0.36 | 0.13 | 127528 |
| 2025-12-18 | NTLA | 8.88 | 0.36 | 0.18 | 127237 |
| 2025-12-19 | NTLA | 9.25 | 0.36 | 0.26 | 126517 |
| 2025-12-22 | NTLA | 9.66 | 0.37 | 0.21 | 111623 |
| 2025-12-23 | NTLA | 9.41 | 0.37 | 0.34 | 113449 |
| 2025-12-26 | NTLA | 9.44 | 0.36 | 0.26 | 114845 |
| 2025-12-29 | NTLA | 9.15 | 0.36 | 0.93 | 115629 |
| 2025-12-30 | NTLA | 9.07 | 0.37 | 0.09 | 116210 |
| 2025-12-31 | NTLA | 8.98 | 0.35 | 0.52 | 116674 |
| 2026-01-02 | NTLA | 9.25 | 0.35 | 0.34 | 116755 |
| 2026-01-05 | NTLA | 9.39 | 0.35 | 1.06 | 117303 |
| 2026-01-06 | NTLA | 9.75 | 0.36 | 0.14 | 118124 |
| 2026-01-07 | NTLA | 10.12 | 0.36 | 0.27 | 118457 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-09 | NTLA | 9.30 | 24.3 | 14.8 | -3.97 |
| 2025-12-10 | NTLA | 9.39 | 24.3 | -7.0 | -3.97 |
| 2025-12-11 | NTLA | 9.56 | 24.3 | -15.0 | -3.97 |
| 2025-12-12 | NTLA | 9.03 | 24.3 | 42.1 | -3.97 |
| 2025-12-15 | NTLA | 9.14 | 24.3 | -9.5 | -3.97 |
| 2025-12-16 | NTLA | 9.14 | 24.3 | 3.0 | -3.97 |
| 2025-12-17 | NTLA | 8.80 | 24.3 | 27.7 | -3.97 |
| 2025-12-18 | NTLA | 8.87 | 24.3 | -6.8 | -3.97 |
| 2025-12-19 | NTLA | 9.25 | 24.3 | -32.4 | -3.97 |
| 2025-12-22 | NTLA | 9.72 | 24.3 | -35.2 | -3.97 |
| 2025-12-23 | NTLA | 9.44 | 24.3 | 23.0 | -3.97 |
| 2025-12-26 | NTLA | 9.44 | 24.0 | 12.8 | -3.97 |
| 2025-12-29 | NTLA | 9.14 | 24.0 | 25.1 | -3.97 |
| 2025-12-30 | NTLA | 9.07 | 24.0 | 6.9 | -3.97 |
| 2025-12-31 | NTLA | 8.98 | 24.0 | 7.2 | -3.97 |
| 2026-01-02 | NTLA | 9.23 | 24.0 | -21.0 | -3.97 |
| 2026-01-05 | NTLA | 9.40 | 24.0 | -15.1 | -3.97 |
| 2026-01-06 | NTLA | 9.75 | 24.0 | -27.7 | -3.97 |
| 2026-01-07 | NTLA | 10.13 | 24.0 | -30.6 | -3.97 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-09 | NTLA | 1.44 | 4.96 | 36.61 |
| 2025-12-10 | NTLA | 1.44 | 4.96 | 40.56 |
| 2025-12-11 | NTLA | 1.44 | 4.96 | 40.56 |
| 2025-12-12 | NTLA | -0.07 | 4.96 | 40.56 |
| 2025-12-15 | NTLA | -0.07 | 4.96 | 40.40 |
| 2025-12-16 | NTLA | -0.08 | 4.96 | 40.40 |
| 2025-12-17 | NTLA | -0.08 | 4.96 | 40.40 |
| 2025-12-18 | NTLA | -0.08 | 4.96 | 40.40 |
| 2025-12-19 | NTLA | -0.08 | 4.96 | 40.40 |
| 2025-12-22 | NTLA | -0.08 | 4.97 | 40.48 |
| 2025-12-23 | NTLA | -0.07 | 4.97 | 40.48 |
| 2025-12-26 | NTLA | -0.07 | 4.97 | 36.85 |
| 2025-12-29 | NTLA | -0.07 | 4.97 | 36.85 |
| 2025-12-30 | NTLA | -0.07 | 4.97 | 36.85 |
| 2025-12-31 | NTLA | -0.07 | 4.97 | 36.85 |
| 2026-01-02 | NTLA | -0.07 | 4.97 | 36.85 |
| 2026-01-05 | NTLA | 0.04 | 4.97 | 36.85 |
| 2026-01-06 | NTLA | 0.04 | 4.97 | 36.85 |
| 2026-01-07 | NTLA | 1.22 | 4.97 | 36.85 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.92
Avg. EPS Est. Current Quarter
-0.97
Avg. EPS Est. Next Quarter
-0.99
Insider Transactions
1.22
Institutional Transactions
4.97
Beta
2.1
Average Sales Estimate Current Quarter
12
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
16
Growth Score
28
Sentiment Score
48
Actual DrawDown %
95
Max Drawdown 5-Year %
-96.4
Target Price
22.12
P/E
Forward P/E
PEG
P/S
20.4
P/B
1.57
P/Free Cash Flow
EPS
-4.27
Average EPS Est. Cur. Y
-3.97
EPS Next Y. (Est.)
-3.59
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-774.94
Relative Volume
0.73
Return on Equity vs Sector %
-86.6
Return on Equity vs Industry %
-71.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
-30.6
Intellia Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 403
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
stock quote shares NTLA – Intellia Therapeutics, Inc. Stock Price stock today
news today NTLA – Intellia Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NTLA – Intellia Therapeutics, Inc. yahoo finance google finance
stock history NTLA – Intellia Therapeutics, Inc. invest stock market
stock prices NTLA premarket after hours
ticker NTLA fair value insiders trading